ChartMill assigns a Buy % Consensus number of 83% to PHIO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2021-06-14 | HC Wainwright & Co. | Maintains | Buy |
7 analysts have analysed PHIO and the average price target is 14.28 USD. This implies a price increase of 1175% is expected in the next year compared to the current price of 1.12.
The consensus rating for PHIO PHARMACEUTICALS CORP (PHIO) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering PHIO PHARMACEUTICALS CORP (PHIO) is 7.